(NASDAQ: ODTX) Odyssey Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 23.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 68.82%.
Odyssey Therapeutics's earnings in 2026 is N/A.On average, 7 Wall Street analysts forecast ODTX's earnings for 2026 to be -$180,905,164, with the lowest ODTX earnings forecast at -$187,341,361, and the highest ODTX earnings forecast at -$162,898,222. On average, 7 Wall Street analysts forecast ODTX's earnings for 2027 to be -$190,088,752, with the lowest ODTX earnings forecast at -$221,232,260, and the highest ODTX earnings forecast at -$146,255,369.
In 2028, ODTX is forecast to generate -$194,377,949 in earnings, with the lowest earnings forecast at -$216,054,484 and the highest earnings forecast at -$149,281,343.